



## ASX ANNOUNCEMENT

### Simavita releases ASX Appendix 4C for the quarter ended June 30, 2019

For Immediate Release:

July 31, 2019

---

**Sydney, Australia** – Simavita Limited (ASX: SVA) today reported its June 30, 2019 quarter end results.

- Simavita continues to tightly manage ongoing operating costs with total cash outflows for the quarter of \$0.99m. This is a decrease of 2.86% on previous quarter. Quarter on quarter there was a \$36k increase in marketing costs.

Forecast cash outflows for the coming quarter are \$1.45m including additional commercialisation and one off software development costs.

- Simavita ended the quarter for the period to June 30, 2019 with cash reserves of AUD\$689k.
- On 24 June 2019 the Company received the approval of shareholders at a Special General Meeting for a \$3.14m financing by way of Convertible Notes. \$1.39m of these funds were received during the quarter and in July a further \$750k was received. The remaining funds of \$1m are due in November and is subject to milestones.
- Funds raised will be used to:
  - Progress key commercialisation activities in major markets
  - Focus on sales and marketing
  - Continue software development for key Apps
  - Deliver key product lines in conjunction with manufacturing partners
  - Continue strategic field testing with partner organisations
  - Complete regulatory approvals in selected markets
  - Progress activities associated with a reorganisation of the Company including branding
  - Provide working capital for the normal operations of the Company over the ensuing months

- The Company continues dialogue with a number of major organisations with specific interest in our platform technology. These discussions are often complex, relate to major installations and may be of varying duration. The Company is committed to informing our shareholders and market should these discussions translate into signed agreements that are material to the Company and its operations.
- The Company expects to have negative operating cash flows for the time being. It should be noted that the Company continues to enjoy the support of its major shareholders. If required, the Company will raise additional cash to fund operations and to meet its business objectives.
- The Company confirms that it continues to be in compliance with Listing Rules 3.1 and 12.2.
- The above statements have been authorised and approved in accordance with the Company's published continuous disclosure policy.

For further information, please view our website ([www.simavita.com](http://www.simavita.com)) or contact:

Ms Peta Jurd  
Chief Commercial Officer

E: [pjurd@simavita.com](mailto:pjurd@simavita.com)  
T: +61 421 466 653  
W: Investor Centre: [Click here](#)

### **About Simavita**

Simavita (ASX: SVA) is a MedTech Company focused on the development of smart, wearable and disposable platform technologies for the health care market.

Our key platform AlertPLUS™ is a highly disruptive technology focused on transforming a traditional “dumb” diaper into a smart device to help parents and carers of both infants and adults.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. [www.simavita.com](http://www.simavita.com)

### **Forward-Looking Information**

*This document may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.*

*Forward-looking information relates to future events or future performance and reflects Simavita management's expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.*

*In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in*

*obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita's interim and annual financial statements and management's discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information*

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

<b>Name of entity</b> <b>SIMAVITA LIMITED</b>
--

<b>ARBN</b> 165 831 309
----------------------------

<b>Quarter ended:</b> 30 June 2019
---------------------------------------

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (nine months) \$A'000
<b>1 Cash flows from operating activities</b>		
1.1 Receipts from customers	22	266
1.2 Payments for		
(a) research and development	(65)	(206)
(b) product manufacturing and operating costs	(18)	(132)
(c) advertising and marketing	(98)	(233)
(d) leased assets	-	-
(e) staff costs	(563)	(2,579)
(f) administration and corporate costs	(254)	(1,377)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	2	4
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	731
1.8 Other: GST refund	18	111
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(956)</b>	<b>(3,415)</b>
<b>2 Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(92)	(154)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(92)</b>	<b>(154)</b>
<b>3 Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	2,075
3.2 Proceeds from issue of convertible notes	1,390	1,390
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	(70)	(115)
3.5 Proceeds from borrowings	-	254
3.6 Repayment of borrowings	-	(709)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.1 Net cash from / (used in) financing activities</b>	<b>1,320</b>	<b>2,895</b>

	<b>Current quarter</b> <b>\$A'000</b>	<b>Year to date</b> <b>(nine months)</b> <b>\$A'000</b>
<b>4 Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	417	1,361
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(956)	(3,415)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(92)	(154)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	1,320	2,895
4.5 Effect of movement in exchange rates on cash held	-	2
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>689</b>	<b>689</b>

	<b>Current quarter</b> <b>\$A'000</b>	<b>Previous quarter</b> <b>\$A'000</b>
<b>5 Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		
5.1 Bank balances	689	417
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)	-	-
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>689</b>	<b>417</b>

	<b>Current quarter</b> <b>\$A'000</b>
<b>6 Payments to directors of the entity and their associates</b>	
6.1 Aggregate amount of payments to these parties included in item 1.2	125
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	Directors' Fees plus superannuation

	<b>Current quarter</b> <b>\$A'000</b>
<b>7 Payments to related entities of the entity and their associates</b>	
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	None

	<b>Total facility amount</b> <b>at quarter end</b> <b>\$A'000</b>	<b>Amount drawn at</b> <b>quarter end</b> <b>\$A'000</b>
<b>8 Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>		
8.1 Loan facilities	4,540	2,790
8.2 Credit standby arrangements	None	None
8.3 Other: 2019 R&D tax incentive-Receiveable Finance Facility	634	254

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.	<p>1) Convertible notes issued in April 2018, totalling \$1.4m which are either convertible or redeemable on 31 March 2020 Coupon rate of 10% per annum, with interest payable on Maturity Date.</p> <p>2) Convertible notes issued in April 2019, totalling \$3.14m which are either convertible or redeemable on 30 April 2022 Coupon rate of 10% per annum, with interest payable on Maturity Date.</p> <p>3) Finance provider: Antra Group Pty Ltd. Loan secured by the Group. Establishment fee at 5% p.a. and capitalised interest at 16% p.a. Facility to be repaid by the Group once the 2019 R&amp;D tax incentive is received from the ATO.</p>
--	---

<b>9 Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	(300)
9.2 Product manufacturing and operating costs	(30)
9.3 Advertising and marketing	(100)
9.4 Leased assets	-
9.5 Staff costs	(600)
9.6 Administration and corporate costs	(420)
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>(1,450)</b>

<b>10 Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity	Not applicable	Not applicable
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here: .....  
Company secretary

Date: 31 July 2019 .....

Print name: Peta C. Jurd

**Notes**

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.